

**Vet Biotechnology Ltd** (ACN 105 577 017)

## **NSX COMPANY ANNOUNCEMENT**

**NSX codes VBL, VBLO**

July 12 2005 at 16:00 EST.

### **Equine Stem Cell Manufacture & Supply Agreement with Medvet Science Pty Ltd**

Vet Biotechnology Ltd has signed a Manufacture and Supply Agreement with Medvet Science Pty Ltd for the manufacture of the equine stem cell services to treat tendon and ligament injuries in horses.

Manufacturing will be conducted at the Therapeutic Products Facility, Department of Haematology, Institute of Medical and Veterinary Science (IMVS) in Adelaide. Medvet acts as IMVS' authorised agent for science and technology commercialisation.

In Australia the provision of equine stem cell services is regulated by the Australian Pesticides and Veterinary Medicines Authority (APVMA). Vet Biotechnology Ltd is required to receive a Minor Use Permit and a Good Manufacturing Practice (GMP) licence both issued by the APVMA. With the receipt of the Minor Use Permit and the GMP licence, commercial manufacture and supply of the equine stem cells may begin in Australia.

Under the Manufacture and Supply Agreement with Medvet Science Pty Ltd the IMVS will supply Vet Biotechnology Ltd with GMP manufacturing facilities and maintain a GMP licence from the APVMA on behalf of Vet Biotechnology Ltd. The IMVS will transfer the equine stem cell manufacturing processes to the Therapeutic Products Facility.

A validation study has been conducted by the IMVS for the purposes of demonstrating GMP compliance. The results of this study have been used by Vet Biotechnology Ltd to apply for a Minor Use Permit from the APVMA.

Medvet must ensure that the stem cell services are performed in accordance with all applicable laws and standards, and in particular, with the Australian veterinary standard of Good Laboratory Practice, GMP and any other requirements of the APVMA Permit.

The IMVS will provide two services for Vet Biotechnology Ltd. The first is the growth of bone marrow derived adult mesenchymal stem cells to treat equine tendon and ligament injuries. The second is the cryo-storage of equine umbilical cord derived mesenchymal stem cells, collected at foaling, and the recovery and growth of equine stem cells for future treatment of tendon and ligament injuries.

With the receipt of the APVMA regulatory approvals, veterinarians trained in the stem cell services by Vet Biotechnology Ltd are able to order the services directly from the IMVS.

Vet Biotechnology Ltd has an exclusive license from VetCell Bioscience Ltd (UK) to market this innovative equine stem cell therapy in Australia and New Zealand. Vet Biotechnology Ltd's NSX listing was underwritten by Sydney based Martin Place Securities Pty Ltd.

For further information, contact:

Hugo Le Messurier  
General Manager  
Vet Biotechnology  
Tel.: 08 8363 1159  
Mobile: 0407 977 553

**Vet Biotechnology Ltd**

ACN 105 577 017  
Suite 7, 114 Rundle Street  
Kent Town South Australia 5067  
Telephone: 61 8 8363 1159 Facsimile: 61 8 8362 2598  
Web page: [www.vetbiotechnology.com.au](http://www.vetbiotechnology.com.au)